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Personalized medicineThe incidence of health problems resulting from obesity is growing and obesity and its related diseases has
become one of the main causes in death in industrialized societies. Environmental inﬂuences are crucial for
the interactions between genetic, neurohormonal and metabolic factors that may be important in
understanding individual differences in the development of obesity and metabolic diseases like type 2
diabetes. In particular the interactions between the personality of an individual and the environment play a
key role in predicting the chance for successful treatment. Our experimental data clearly point out that the
success of interventions designed to prevent or treat metabolic diseases could be considerably improved by
adjusting the intervention to the personality of the individual. Furthermore, certain physiological and
neuroendocrine characteristics of a personality are strong indicators for pathology development, both in
experimental animals and humans. Future research should focus on the identiﬁcation of easily measurable
physiological and neuroendocrine markers indicative of the coping style or personality in humans.eurosciences, Department of
1103, 9700 CC Groningen, The
331.
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
In this perspective we argue that a deeper insight in the relation
between the personality of an individual and the coherent neuroen-
docrine background may provide an important impulse to the
personalized healthcare initiatives that are currently undertaken by
the pharmaceutical industry and healthcare systems. Ideally, it will
facilitate “tailor made” pharmacological treatment strategies, in
which patients are subjected to treatments with optimal efﬁcacy. A
key element here is the idea that different populations of patients can
suffer from what superﬁcially appears a common disease, but in
which the etiology of the disease is, in part, driven by speciﬁc traits
linked to personality and the neuroendocrine system. Focusing on
underpinnings and progression of disease in these speciﬁc patient
populations – rather than targeting the common disease character-
istics displayed by the group as a whole – this may drastically limit the
number of patients that are exposed to treatments from which they
do not beneﬁt. This will help reducing the burden on health care
providers and the ever-increasing costs of our healthcare system,
which is becoming a staggering threat to our society In this
perspective, we speciﬁcally focus on the role an individual's
personality is playing in the success of both pharmacological and
life style treatments of insulin resistance, which is a major risk-factor
for type 2 diabetes.2. Personality
The number of people developing obesity, and obesity-related
disorders is ever increasing (World Health Organisation, 2010).
Obesity can be caused by single gene mutations or polymorphisms
(Jackson et al., 1997; Montague et al., 1997; Vaisse et al., 1998; Yeo
et al., 1998); (Frayling et al., 2007; Hara et al., 2002; Lyssenko et al.,
2009; Staiger et al., 2009; van et al., 2008). However, evidence is
accumulating that genetic mutations are not the main cause of the
dramatic increase in the incidence of obesity and type 2 diabetes in
Western societies over the last decades (Chakravarthy and Booth,
2004; Speakman, 2008; Wells, 2006). Generational accumulation of
environmental inﬂuences appears to add another layer to the
interactions between genetic, neurohormonal and metabolic factors
that may be a key in understanding individual differences in the
development of obesity and metabolic diseases.
The way an individual perceives and interacts with the environ-
ment is to a large extent determined by the individual's personality.
Personality can be deﬁned as a set of behavioral strategies that are
embedded within the individual. These behavioral strategies are
deployed throughout life to guide the individual's interaction with the
environment (Thurstone, 1987). In most animal species, including
humans, two major personality types can be distinguished (reviewed
in (Koolhaas et al., 1999). The proactive (type A) personality is
characterized by the so-called “ﬁght/ﬂight” response. Individuals with
this personality type display high levels of aggression, impulsivity and
often develop routine behaviors (Benus et al., 1991; van Oortmerssen
and Bakker, 1981). The passive (type B) personality originates from a
“conservation/withdrawal” response (Engel and Schmale, 1972).
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aggressive nature, low levels of cue dependency and high levels of
behavioral ﬂexibility. The proactive (type A) personality seems to
have evolved to assure ﬁtness under stable environmental conditions.
This individual is capable to defend a territory against intruders, due
to the higher levels of aggression. However, due to its sensitivity to
routine formation it will have difﬁculties to cope with relatively large
changes in the environment, which the animal/individual has no
inﬂuence on. In contrast, the passive (type B) personality is not
aggressive and very ﬂexible in its behavior. It will be more successful
in an ever changing environment, since it will adapt to the prevailing
condition. In nature, for example, type B ﬂexible animals may migrate
to avoid psychosocial pressure from conspeciﬁcs or predation by
others, while type A animals will stick and face the challenge
(Koolhaas et al., 1999).
3. Personality and development of insulin resistance
In consideration of the apparent relation between treatment
efﬁcacy and personality type it is in the ﬁrst place important to realize
that there are potential differences in the susceptibility to develop a
disorder and/or differences in the origin of the disorder. The role of
personality in the development of type 2 diabetes has been studied in
humans as well as in rodents. Data from studies in human are
contradictory; i.e., some studies show an increased risk for type 2
diabetes in individuals characterized by high levels of hostility and
extraversion, while others show the complete opposite (reviewed in
Smith and MacKenzie, 2006). The discrepancy between the studies
seems to originate mostly from differences in the methodology used
to assess an individual's personality. Studies using a questionnaire to
assess personality type generally indicate an increased risk for insulin
resistance in type A personalities (Yancura et al., 2006). In contrast,
studies focused on the differential physiological characteristics of the
personality types ﬁnd a stronger relation between the type B
personality type and metabolic risk (Phillips et al., 2010). Studies in
rodent models generally seem to indicate that rats with a passive
(type B) personality aremore prone to develop insulin resistance than
rats with a pro-active (type A) personality.
Although there is some discrepancy in the human studies, data
from both human and rodent studies indicate that individuals with
elevated HPA-axis responses – typically found in the passive
personality types – are more prone to develop insulin resistance
than thosewith a lowHPA axis responsiveness (Boersma et al., 2011a;
Marissal-Arvy et al., 2007; Phillips et al., 2010). In our laboratory, we
observed these speciﬁcities in different animal models including the
outbred Wild Type Groningen rat characterized by a passive coping
style, and the passive Roman Low Avoidance inbred rat strain
(Boersma et al., 2011b), both displaying HPA axis hyperactivity and
disturbances in insulin action (evidenced by a hyperinsulinemic
response to an intravenous glucose tolerance test under sedentary
conditions) (Boersma et al., 2010). Likewise, several studies by others
have shown that Fischer rats, characterized by elevated Hypothala-
mus–Pituitary–Adrenal-axis (HPA-axis) reactivity, develop insulin
resistance at a later age (Fink et al., 1980; Marissal-Arvy et al., 2007).
We may thus conclude that at least some of the physiological
characteristics that are typical for the passive personality type may
serve as risk factors for the development of insulin resistance.
4. Personality and treatment of insulin resistance
Onemay argue that an individual's personality may also play a role
in the treatment efﬁcacy. Treatment of type 2 diabetes and insulin
resistance can generally be dissociated in two different approaches.
The ﬁrst approach aims at reducing symptoms by directly interfering
with the glucose and insulin signaling pathways. These, mostly
pharmacological, interventions generally circumvent the origin of theproblem and the efﬁcacy of these kinds of interventions are therefore
independent of the environment of the individual. A second approach
is more aimed at eliminating the origin of the obesity and thereby
decreasing symptoms. Life style interventions are good examples of
the latter. In the following paragraphs we will focus on the role of
personality on both of these treatment strategies.
First, we focus on the pharmacological interventions aimed at
reduction of insulin resistance. Metformin and Thiazolidinediones are
the most frequently employed pharmacological treatments for insulin
resistance. Both drug types aim at increasing glucose transport and
decreasing circulating glucose levels (Saltiel and Olefsky, 1996;
Spiegelman, 1998). On average, treatment with either Metformin or
Thiazolidinediones results in a reduction of the HbA1c concentration
with approximately 8% after a year of treatment. However, results for
different individuals vary between 6 and 12% reduction (Schernthaner
et al., 2004). To our knowledge there are no studies in humans that
have investigated differences in efﬁcacy of these agents in the
different personality types. In a rat study we, however, have shown
that treatment with the Thiazolidinedione, Rosiglitazone, lowered the
insulin response during an intravenous glucose tolerance test in both
passive and proactive (Boersma et al., 2011a). For these drugs it thus
seems that the personality does not play a major role in the treatment
efﬁcacy.
Recently, another class of drugs has been developed aiming at
lowering glucocorticoid levels and thereby reducing the insensitivity
of the insulin receptor. Originally, these drugs were administered to
patients with chronically elevated glucocorticoid levels such as
patients with Cushing syndrome (Johanssen and Allolio, 2007),
However, currently these drugs also proved to be beneﬁcial for the
average diabetes patient (Combettes and Kargar, 2007). This third
class of therapeutic agents may be of interest since passive
personalities are characterized by moderately elevated glucocorticoid
levels (Aubry et al., 1995; Boersma et al., 2009; Fernandez-Teruel
et al., 1997; Gentsch et al., 1982). Unfortunately, up till now there are
no studies available in the literature that focus on the efﬁcacy of these
drugs in humans characterized on the basis of their personality.
Studies in rats are nevertheless promising. In a recent article
published in European Journal of Pharmacology, we showed that
RU486, a glucocorticoid receptor antagonist, improved hyperinsuli-
neamia solely in rats with the passive personality, by targeting the
speciﬁc hormonal characteristics of this coping style (Boersma et al.,
2011a).
One should note that personality may affect the treatment of
insulin resistance through two different pathways. Knowledge on the
personality may help to match the pharmacological treatment of the
patient with his/her neuroendocrine characteristics. But knowledge
on the personality type of the patient may also prove to be important
to predict the compliance of these patients to non-pharmacological
treatments such as dieting and increased physical activity. Generally,
these life style interventions are effective in lowering both body
weight and improving insulin signaling (Torjesen et al., 1997).
However, there are indications that the efﬁcacy of– and/or compliance
to– these life style intervention programs are directly associated to
the personality of the individual (Hassmen et al., 1993; Ryden et al.,
2001). The proactive personality type was shown to have stronger
internal motivation to perform an exercise protocol, while the passive
personality type appears to respond better to instructions and may
therefore perform better during life style interventions (Hassmen
et al., 1993). In our studies we have found that when experimental
rats were offered access to a running wheel in which the animals can
voluntarily exercise, rats with a passive personality tend to run more,
particularly when they were fed on a palatable, high-fat diet, And
even more striking, rats with a passive personality seem to adapt the
level of physical activity to their energy intake, whereas proactive rats
do not (Boersma et al., 2011b). We concluded from this that the
passive personality type might be more receptive to life style
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seems to support this view since we found recently that obese
individuals with a passive personality showed stronger increases in
physical activity andmore profoundly improved dietary habits during
a lifestyle intervention, when compared to their proactive counter-
parts. A more detailed investigation of their activity pattern, however,
leads us to believe that passive individuals also have compensatory
responses on the days they do not have to perform guided exercise
(Boersma, 2011). This latter observation indeed conﬁrms our
hypothesis that the individuals with a more passive personality are
more susceptible to environmental cues.
5. Conclusions
Progressive knowledge indicates that the interactions between the
personality of an individual and the environment are crucial in
understanding individual differences in both the development and
the treatment of metabolic diseases such as obesity and insulin
resistance. Data clearly point out that the success of both pharmaco-
logical and life style interventions for prevention and/or treatment of
metabolic diseases could be considerably improved by adjusting the
intervention to the personality of the individual. Furthermore,
experiments in laboratory rodents clearly reveal that certain
physiological and/neuroendocrine characteristics related to person-
ality are strong indicators for pathology development. In humans the
relation between the assessed personality types and these physiolog-
ical and neuro-endocrine parameters are less clear. Future research
should therefore focus on the identiﬁcation of easily assessable
physiological/neuro-endocrine biomarkers of coping style in humans.
These biomarkers and tailored interventions may help to halt or even
arrest the current epidemic in metabolic diseases. Finally, improved
understanding of the evolutionary basis and epigenetic mechanism
underlying the link between personality and energy balance and fuel
homeostasis may prove to be an important angle to understand
development of metabolic derangements.
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